Revenue segments as reported by the company.

Premiums

Services

Investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefits

Operating costs

Depreciation and amortization

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Humana

Humana Inc. engages in the provision of health insurance services. The firm operates through the following segments: Retail, Group and Specialty and Healthcare Services. The Retail segment consists of products sold on a retail basis to individuals including medical and supplemental plans such as Medicare, and State-based contracts. The Group and Specialty segment contains employer group fully-insured commercial medical products and specialty health insurance benefits marketed to individuals and groups, including dental, vision, military services and other supplemental health & voluntary insurance. The Healthcare Services segment offers services such as pharmacy solutions, provider services, clinical care, predictive modeling and informatics to other Humana businesses, as well as external health plan members, and other employers. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Humana exceeds earnings expectations, focuses on value-based care growth

Humana's strong financial performance and growth in value-based care position the company well for future success. Addressing audit error rates, uncertainties around RADV, and managing costs are key challenges. Opportunities in recruiting, revenue growth, and strategic partnerships offer avenues for further growth.

Humana exceeds Q1 expectations, eyes industry growth amidst challenges

Humana's strong Q1 performance and strategic decisions position it well for growth
Challenges like rate disruptions and Medicaid redeterminations require close monitoring
Opportunities in industry growth, member engagement, and benefit enhancements ahead
Commitment to long-term goals and high-quality service evident in company's outlook

Humana meets Q2 expectations, eyes growth in MA platform

Humana's Q2 performance met expectations with a focus on MA platform growth and disciplined investments.
Challenges include higher utilization in Medicare Advantage and broad-based medical cost trends.
Strategic benefits adjustments and competitive positioning present opportunities for growth and margin expansion.
Expectations for 2024 include maintaining market share, offsetting costs, and achieving strong membership growth.

Humana surpasses Q3 earnings expectations, eyes $37 EPS target

Humana's Q3 performance exceeded expectations, with strong membership growth and strategic initiatives driving future profitability.
While facing challenges in benefit ratios and regulatory changes, Humana remains focused on achieving long-term financial targets.
The company's commitment to operational excellence, membership growth, and pricing actions positions it for sustained success.
Strategic partnerships and risk management efforts showcase Humana's resilience and adaptability in a dynamic healthcare landscape.

Humana faces challenges from rising costs but eyes long-term growth

Humana's Q4 2023 earnings call highlighted challenges from increased medical costs and utilization trends impacting financial performance and outlook.
Despite disappointments in short-term results, the company remains confident in the long-term attractiveness of the Medicare Advantage sector.
Strategic efforts to restore margins, address utilization drivers, and engage with providers reflect a proactive approach to managing industry dynamics.
Balancing profitability with membership growth through benefit adjustments and pricing actions is crucial for Humana's sustainable financial performance.

Humana reports solid Q1 performance, eyes margin recovery in 2025

Humana's Q1 2024 earnings call highlighted a strong start to the year, challenges in the industry for 2025, and a focus on margin recovery and growth opportunities. The company remains confident in its outlook, emphasizing pricing discipline and maintaining a strong value proposition in the market.

Humana surpasses Q2 expectations, addresses cost pressures for growth

Humana's Q2 2024 performance exceeded expectations, driven by strong Medicare business and growth in Medicaid and primary care segments.
Challenges such as medical cost pressures were addressed through mitigation measures, while opportunities lie in strategic initiatives and long-term planning.
The company's focus on value, disciplined cost management, and operational efficiency position it well for sustained growth and value creation.

Humana surpasses Q3 expectations, eyes growth through efficiency and investments

Humana's Q3 performance exceeded expectations, with a focus on balancing earnings and investments. The company is strategically positioned to drive growth through membership expansion and operational efficiency. Challenges include managing costs and understanding market dynamics, with opportunities in improving Stars ratings and expanding senior care services.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Humana Inc. engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts. The CenterWell segment represents payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) announced today that Bruce D. Broussard, President and Chief Executive Officer, will make a presentation to investors at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022 at 11:20 a.m. Eastern time. A live audio webcast of the presentation will be available via Humana's Investor Relations page at humana.com. The company suggests webcast participants sign on approximately 15 minutes in advance of the pr

Humana Inc. to Present at the 11th Annual SVB Leerink Global Healthcare Conference

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana earns top score in Human Rights Campaign Foundation's 2022 corporate equality index

Humana Earns Top Score in Human Rights Campaign Foundation's 2022 Corporate Equality Index

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Specialty Pharmacy expands access to new cancer treatment options.

Humana Specialty Pharmacy Expands Access to New Cancer Treatment Options

Humana (HUM) is taking multiple initiatives like cost savings and others to generate $1 billion additional value to fund the Medicare Advantage business and boost Healthcare Services capabilities.

Humana (HUM) Q4 Earnings Beat Estimates on Membership Growth

Humana's (HUM) CEO Bruce Broussard on Q4 2021 Results - Earnings Call Transcript

Humana (HUM) delivered earnings and revenue surprises of 0.81% and 0.62%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Humana (HUM) Q4 Earnings Surpass Estimates

Humana Inc  HUM posts Q4 adjusted sales of $21.19 billion, missing the consensus of $21.23 billion. Thousands of new traders are learning the ins and outs on how to find profitable trades every day with Benzinga Trading School.

Humana Q4 Bottom-Line Beats Expectations, Plans Cost Savings

Humana Inc. HUM, -0.46% reported Wednesday that it swung to a fourth-quarter adjusted profit that beat expectations but revenue that came up a bit short, and said it would invest $1 billion to help grow its Medicare Advantage business. The health insurer's stock was still inactive in premarket trading.

Humana beats profit expectations but revenue comes up shy, to invest $1 billion in its Medicare Advantage business

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) today reported consolidated pretax results and results per common share for the quarter ended December 31, 2021 (4Q21) versus the quarter ended December 31, 2020 (4Q20) and for the year ended December 31, 2021 (FY 2021) versus the year ended December 31, 2020 (FY 2020) as noted in the tables below. Consolidated (loss) income before income taxes and equity in net earnings (pretax results) In millions 4Q21 (a) 4Q20 (b) FY 2021 (c) FY 2020

Humana Reports Fourth Quarter 2021 Financial Results; Provides Full Year 2022 Financial Guidance

AbbVie

Marathon Petroleum

Novartis

U.S. equity markets opened mixed on Monday, with the Dow Jones industrials lagging and the tech-heavy Nasdaq adding about 1.5% in the early going.

Earnings Previews: AbbVie, Humana, Marathon Petroleum, Novartis

Humana's (HUM) fourth-quarter results are likely to reflect growth in medical membership.

Retail Loss to Affect Humana's (HUM) Q4 Earnings: Here's How

LOUISVILLE, Ky.--(BUSINESS WIRE)--Go365 by Humana announces winners of National Step Challenge, resulting in 7.2 billion steps taken and one million meals donated to Feeding America.

Go365® by Humana Announces Winners of Fourth Annual National Step Challenge, Resulting in 7.2 Billion Steps Taken and One Million Meals Donated to Feeding America®

UnitedHealth Group

UnitedHealth Group Inc. dispelled worries about its Medicare Advantage business, saying its tracking “very much in line” with expectations, after rival Humana Inc. had raised concerns by blaming an evolution in competition for its own Medicare growth problems.

UnitedHealth said Medicare Advantage competition isn't new, and is good for the company and seniors; that's not what rival Humana said

LOUISVILLE, Ky.--(BUSINESS WIRE)--Already the nation's largest provider of senior-focused primary care, CenterWell Senior Primary Care will continue its rapid growth in 2022, with plans to expand into new markets including the Dallas-Ft. Worth metroplex, Phoenix, Louisville, Nashville, and Charlotte. The expansion, which begins later this year and will carry over into early 2023, will mark CenterWell's first ventures into Arizona, Kentucky and Tennessee. A total of 26 centers are planned in thi

CenterWell Senior Primary Care Announces Expansion Plan for 2022 – Phoenix, Dallas, Ft. Worth, Nashville, Charlotte and Louisville New CenterWell Markets

LOUISVILLE, Ky.--(BUSINESS WIRE)--Leading health insurer and health care services company Humana Inc. (NYSE: HUM) has hired health care industry veteran Andrew (Andy) Agwunobi, M.D., MBA, as the new President of the company's Home Solutions business. Dr. Agwunobi comes to Humana from the University of Connecticut, where he currently serves as interim University President, and as CEO of the UConn Health System. In his new role, Dr. Agwunobi will report directly to Humana President and CEO Bruce

Humana Names Dr. Andrew Agwunobi President of Company's Home Solutions Business

Humana (HUM) to buy back shares worth $1 billion as part of its $3-billion share repurchase plan announced in February 2021. This suggests its commitment toward delivering a long-term shareholder value.

Humana (HUM) to Buy Back Shares of $1B to Add Shareholder Value

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) will release its financial results for the fourth quarter 2021 (4Q21) on Wednesday, February 2, 2022 at 6:30 a.m. Eastern time. The company will host a conference call at 9:00 a.m. Eastern time that morning to discuss its financial results for the quarter and earnings guidance for 2022. To participate via telephone, please register in advance at this link. Upon registration, telephone participants will receive a confirmation email detail

Humana Inc. to Release Fourth Quarter 2021 Results on February 2, 2022

Shares of Humana Inc. HUM, +1.68% rallied 1.4% in premarket trading Wednesday, after the health insurer disclosed a $1.0 billion accelerated share repurchase agreement. The ASR, which is part of the $3.0 billion share repurchase program announced in February 2021, represents about 2% of Humana's market capitalization of $50.3 billion as of Tuesday's close.

Humana stock extends bounce after $1 billion ASR announced

The stock of Humana has seen a large fall of 17% over the last month, while it was down around 22% last week. HUM stock rose from levels of around $390 in early October 2021 to levels of around $470 toward the end of the year, before falling to levels of $363 currently.

Will Humana Stock Rebound After A Large Fall Last Week?

Netflix

Here are 3 ugly charts of great stocks to buy on dips. Investor sentiment is largely to blame, so there will be buyers lurking below.

3 Technically Ugly Charts of Good Stocks to Buy on Dips

Shares of Humana Inc. extended their plunge toward a near two-year low on Friday, as some Wall Street analysts expressed concern that there isn't a fast fix to the health insurance services company's Medicare Advantage woes.

Humana's stock keeps falling amid fears that Medicare Advantage problems will last into next year

Humana (HUM) expects Group Medicare Advantage membership to remain flat in 2022, with competitive pricing possibly playing a crucial role.

Humana (HUM) Cuts Medicare Enrollment Outlook, Tumbles 19.4%

Anthem

Cigna

Fifth Third Bancorp

PNC Financial Services

Stocks remained in the red for another session Thursday but at least largely slowed their downward momentum.

Stock Market Today: Health Insurers Lead Another Slide in Stocks

Shares of Humana Inc. HUM, -13.52% tumbled 13.0% toward a three-month low in afternoon trading Thursday, to pace the S&P 500's SPX, +0.26% decliners, after the health insurance services company slashed its full-year membership estimate for its Medicare Advantage products. Humana's stock was headed for the biggest one-day selloff since it slid 13.9% on March 16, 2020.

Humana stock tumbles to pace S&P 500 losers after slashing Medicare Advantage membership growth view

Humana (HUM) collaborates with Vancouver Clinic to boost its Medicare Advantage portfolio.

News for Humana Stock (HUM)